These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15793936)

  • 21. [New protease inhibitor for PI pretreated patients. Tipranavir targets also multiresistant viruses].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():60-1. PubMed ID: 15373052
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA approves tipranavir.
    IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
    [No Abstract]   [Full Text] [Related]  

  • 23. Tipranavir: a protease inhibitor for HIV salvage therapy.
    Dong BJ; Cocohoba JM
    Ann Pharmacother; 2006; 40(7-8):1311-21. PubMed ID: 16788094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tipranavir (Aptivus) for HIV.
    Med Lett Drugs Ther; 2005 Oct; 47(1219):83-4. PubMed ID: 16247341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
    Llibre JM; Pérez-Alvarez N
    HIV Med; 2007 Nov; 8(8):568-70; author reply 571-2. PubMed ID: 17944691
    [No Abstract]   [Full Text] [Related]  

  • 27. New black box warning for ritonavir-boosted tipranavir.
    Ryan CT
    AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment outcome with anti-HIV agent Tipranavir].
    Dtsch Med Wochenschr; 2003 May; 128(19):1073. PubMed ID: 12774795
    [No Abstract]   [Full Text] [Related]  

  • 29. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.
    Best B; Haubrich R
    Expert Opin Investig Drugs; 2006 Jan; 15(1):59-70. PubMed ID: 16370934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updates on developments in HIV therapeutics.
    Boyle BA
    AIDS Read; 2005 Jan; 15(1):23-7. PubMed ID: 15685731
    [No Abstract]   [Full Text] [Related]  

  • 31. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
    Lascar M; Cartledge JD
    J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
    [No Abstract]   [Full Text] [Related]  

  • 32. Some existing drugs work on resistant HIV.
    AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tipranavir.
    Flexner C; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Dec; 4(12):955-6. PubMed ID: 16370086
    [No Abstract]   [Full Text] [Related]  

  • 34. New protease inhibitor offers clinicians hope for better salvage therapy.
    Murphy MJ
    HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
    [No Abstract]   [Full Text] [Related]  

  • 35. New drugs: ramelteon, tipranavir, nepafenac, and deferasirox.
    Hussar DA
    J Am Pharm Assoc (2003); 2006; 46(1):107-11. PubMed ID: 16529348
    [No Abstract]   [Full Text] [Related]  

  • 36. 48-weeks of the RESIST trials.
    Garcia-Gasco P
    AIDS Rev; 2006; 8(1):45. PubMed ID: 16736952
    [No Abstract]   [Full Text] [Related]  

  • 37. New therapy for advanced HIV.
    FDA Consum; 2005; 39(5):5. PubMed ID: 16419282
    [No Abstract]   [Full Text] [Related]  

  • 38. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
    AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
    [No Abstract]   [Full Text] [Related]  

  • 39. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.